192 related articles for article (PubMed ID: 23815013)
1. [Pathophysiological advances underlying the biotherapeutic revolution in inflammatory rheumatism].
Mariette X
Bull Acad Natl Med; 2012 Oct; 196(7):1261-76; discussion 1276-8. PubMed ID: 23815013
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of B cells for rheumatic autoimmune diseases.
Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X
Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206
[TBL] [Abstract][Full Text] [Related]
3. Anti-cytokine antibodies for rheumatic diseases.
Atzeni F; Sarzi-Puttini P
Curr Opin Investig Drugs; 2009 Nov; 10(11):1204-11. PubMed ID: 19876788
[TBL] [Abstract][Full Text] [Related]
4. Anti-cyclic citrullinated peptide versus anti-Sa antibodies in diagnosis of rheumatoid arthritis in an outpatient clinic for connective tissue disease and spondyloarthritis.
López-Longo FJ; Rodríguez-Mahou M; Sánchez-Ramón S; Estecha A; Balsera M; Plaza R; Fernández-Cruz E; Pérez LC
J Rheumatol; 2006 Aug; 33(8):1476-81. PubMed ID: 16881106
[TBL] [Abstract][Full Text] [Related]
5. New cytokine targets in inflammatory rheumatic diseases.
Connell L; McInnes IB
Best Pract Res Clin Rheumatol; 2006 Oct; 20(5):865-78. PubMed ID: 16980211
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological management of inflammatory rheumatic conditions].
Bannwarth B
Therapie; 2011; 66(5):377-81. PubMed ID: 22031680
[TBL] [Abstract][Full Text] [Related]
7. TNF alpha as a therapeutic target in rheumatoid arthritis.
Feldmann M; Brennan FM; Elliott M; Katsikis P; Maini RN
Circ Shock; 1994 Aug; 43(4):179-84. PubMed ID: 7895323
[TBL] [Abstract][Full Text] [Related]
8. Anti citrullinated protein antibodies and mechanism of action of common disease modifying drugs--insights in pathomechanisms of autoimmunity.
Pongratz G; Fleck M
Curr Pharm Des; 2012; 18(29):4526-36. PubMed ID: 22612739
[TBL] [Abstract][Full Text] [Related]
9. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy.
Eklund KK
Immunol Rev; 2007 Jun; 217():38-52. PubMed ID: 17498050
[TBL] [Abstract][Full Text] [Related]
10. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis.
Bokarewa M; Lindblad S; Bokarew D; Tarkowski A
Arthritis Res Ther; 2005; 7(2):R349-58. PubMed ID: 15743483
[TBL] [Abstract][Full Text] [Related]
11. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
[TBL] [Abstract][Full Text] [Related]
12. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Vis M; van der Horst AR; Wolbink GJ; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Lems WF; Nurmohamed MT; Aarden L; Hamann D
Ann Rheum Dis; 2009 Apr; 68(4):558-63. PubMed ID: 18445623
[TBL] [Abstract][Full Text] [Related]
13. Immunologic rheumatic disorders.
Joseph A; Brasington R; Kahl L; Ranganathan P; Cheng TP; Atkinson J
J Allergy Clin Immunol; 2010 Feb; 125(2 Suppl 2):S204-15. PubMed ID: 20176259
[TBL] [Abstract][Full Text] [Related]
14. Expanding possibilities in the treatment of patient groups with previously difficult-to-treat patients.
Dörner T; Burmester GR
Curr Opin Rheumatol; 2010 May; 22(3):235-6. PubMed ID: 20351494
[No Abstract] [Full Text] [Related]
15. Citrullination of autoantigens: upstream of TNFα in the pathogenesis of rheumatoid arthritis.
Quirke AM; Fisher BA; Kinloch AJ; Venables PJ
FEBS Lett; 2011 Dec; 585(23):3681-8. PubMed ID: 21704035
[TBL] [Abstract][Full Text] [Related]
16. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
17. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
18. [Importance of the dense fine speckled pattern and anti-DFS70 antibodies for the diagnosis of systemic autoimmune rheumatic diseases].
López Sañudo S; Fernández Alonso I; López Hoyos M
Med Clin (Barc); 2015 Sep; 145(5):218-23. PubMed ID: 26021571
[No Abstract] [Full Text] [Related]
19. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
20. The BAFF/APRIL system: an important player in systemic rheumatic diseases.
Mackay F; Sierro F; Grey ST; Gordon TP
Curr Dir Autoimmun; 2005; 8():243-65. PubMed ID: 15564724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
